Royal Bank of Canada
ERNA icon

Royal Bank of Canada’s Eterna Therapeutics ERNA Stock Holding History

Royal Bank of Canada’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Hold
0
– – – 7006
2024
Q2 		– Hold
0
– – – 7182
2024
Q1 		– Hold
0
– – – 7157
2023
Q4 		– Hold
0
– – – 7243
2023
Q3 		– Hold
0
– – – 7207
2023
Q2 		– Hold
0
– – – 7362
2022
Q4 		– Sell
-1
Closed -$1K – 7351
2022
Q3 		$1K Buy
+1
New +$3.45K ﹤0.01% 7177
2022
Q2 		– Hold
0
– -$4K – 7458
2022
Q1 		– Sell
-1
Closed -$19K – 7311
2021
Q4 		$28K Hold
1
– – ﹤0.01% 6642
2021
Q3 		$37K Buy
+1
New +$86.3K ﹤0.01% 6337
2021
Q2 		– Hold
0
– – – 6361

Other funds holding ERNA

Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
SCA
Sippican Capital Advisors Boston, Massachusetts $164M AUM 35.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AWE
Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return

Royal Bank of Canada's ERNA Position: Q3 2024 in Review

Royal Bank of Canada held its Eterna Therapeutics (ERNA) position steady in Q3 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7006.

Royal Bank of Canada first reported a position in ERNA in Q3 2021 and has held it in 3 quarters since. The position peaked at $37K in Q3 2021. 13 funds tracked by Wall St. Rank hold ERNA as of Q3 2024.

  • Royal Bank of Canada held 0 shares of Eterna Therapeutics worth $0 as of Q3 2024.
  • Royal Bank of Canada left its Eterna Therapeutics share count unchanged in Q3 2024.
  • Eterna Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q3 2024, its #7006 holding.
  • Royal Bank of Canada first reported a position in Eterna Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Royal Bank of Canada's Eterna Therapeutics position peaked at $37K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.